Relmada Therapeutics pivots to NDV-01 for bladder cancer & Sepranolone for Tourette's. Phase 2 results expected April 2025.
The field of gene editing recently got a major boost from Massachusetts-based Beam Therapeutics, and the company’s Durham ...
The therapies are poised to revolutionize the cancer care landscape, but it will require collaboration across the industry, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback